MOUNTAIN VIEW, Calif., June 11 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver three presentations at the Population Approach Group in Europe (PAGE) 16th Annual Meeting in Copenhagen, Denmark on June 13-15, 2007. Robert Leary, Ph.D., senior software engineer, will present work on computational algorithms and tools; Mike Dunlavey, Ph.D., senior software engineer, will present a next generation language for use in optimizing drug development; and Tim Sheiner, senior product designer, will speak on effectively communicating modeling information to decision-makers.
Pharsight will present during a plenary conference session and at two methodology-focused poster sessions, each of which will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight’s three presentations are:
-- June 14: An Evolutionary Nonparametric NLME Algorithm Dr. Leary will present an improved algorithm for one type of nonlinear mixed effects (NLME) analysis. Through use of a result from the field of optimal design, the approach defines an improvement over other nonparametric approaches in NLME modeling. This work complements discussions of other NLME algorithms by Dr. Leary at past PAGE conferences. -- June 13: Next Generation Modeling Language Dr. Dunlavey will present a new language for control of both population pharmacokinetic/pharmacodynamic (PK/PD) model fitting and trial simulation, to more easily express advanced models, and to facilitate the transition from fitted models to trial designs. -- June 14: Planning to Communicate Mr. Sheiner will present a structured planning framework for communicating complex model-based information with other scientific experts and non-specialists who are involved in drug development decision-making, and will illustrate the value of using appropriate communication tools in this process.
Additional information can be found at: http://www.page-meeting.org.
“Model-based drug development, as recognized by the FDA in its Critical Path Initiative, continues to show value for improving the quality of drug development decisions,” said Shawn O’Connor, president, CEO, and chairman of Pharsight. “The development of advanced computational tools, next generation languages and comprehensive communication strategies are integral to the development of this field. We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers’ specific needs. We look forward to presenting on specific elements of our vision for the future of model-based drug development, and are proud to have such a wide presence at PAGE this year.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or DouglasSherk, +1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, allof EVC Group for Pharsight Corporation
Web site: http://www.pharsight.com/
